Kornimate/medical-research-clean huggingface dataset:
postoperative delirium in cardiac surgery icu

Conditions: Delirium

Summary: postoperative delirium (pod) is a common complication in patients after cardiac surgery, which is associated with short-term prognosis and long-term quality of life. due to the lack of specific treatment, prevention is the most effective strategy to reduce delirium. risk assessment greatly contributes to guide prevention by stratifying the risk of the pod. however, the high-quality risk assessment tools are still sparse, and the combination of risk assessment and stratified prevention has not been applied to the management of delirium after cardiac surgery. in the previous work, we found the predictive value of preoperative cardiac function on pod, and found a critical value. on the basis of previous research, this project will learn from previous studies on risk factors of pod, and deeply explore potential predictors. furthermore, we will develop and validate pod risk prediction model, and then develop it into a visual evaluation system. in addition, based on the theory of risk management and risk assessment tools, using the concepts and methods of evidence-based medicine, the risk assessment system and stratified management program of pod will be formed and evaluated by expert discussion meetings. it is expected that the risk assessment system and stratified management program constructed by this project could simply and quickly screen high-risk patients and carry out timely intervention, so as to reduce the incidence of pod, improve patients' prognosis and the quality of life after cardiac surgery.


Eligibility criteria:
inclusion criteria: * aged above 18 * patients after cardiac surgery * admitted to icu after surgery exclusion criteria: * preoperative delirium or dementia patients * unable to fully participate in delirium testing, including blind, deaf, illiterate or inability to understand chinese * undergoing surgery procedures do not require admission to sicu * transfer to icu from wards after surgery

Keywords: postoperative delirium cardiac surgery intensive care unit risk assessment
predictive tools for the presence of significant coronary artery disease requiring intervention in chronic hemodialysis patients

Conditions: Hemodialysis; Coronary Arterial Disease (CAD); ESRD (End Stage Renal Disease)

Summary: medical record data of all hd patients undergoing coronary angiography (cag) at king chulalongkorn memorial hospital between january 2017 and march 2021 were retrospectively reviewed as a discovery cohort to identify factors discriminating patients with and without significant cag-established cad. hd patients receiving cag between april 2021 and march 2023 were assigned as a validation cohort.

background: hemodialysis (hd) patients have increased cardiovascular risk. coronary artery disease (cad) may not typically manifest in these patients and the investigational results can be confounded by the fluctuation of body fluid and electrolytes. this study explored the accuracy of these findings in identifying cad in hd patients. methods: medical record data of all hd patients undergoing coronary angiography (cag) at king chulalongkorn memorial hospital between january 2017 and march 2021 were retrospectively reviewed as a discovery cohort to identify factors discriminating patients with and without significant cag-established cad. hd patients receiving cag between april 2021 and march 2023 were assigned as a validation cohort.

Eligibility criteria:
inclusion criteria: * all adult hd patients undergoing cag at king chulalongkorn memorial hospital of all indications between january 2017 and march 2021 with complete data exclusion criteria: * those resinged for using their clinical data for the research

Keywords: hemodialysis coronary artery disease electrocardiography echocardiography troponin coronary angiography
an evaluation of three dose levels of 3-antigen staphylococcus aureus vaccine (sa3ag) in healthy adults

Conditions: Bacterial Infections; Staphylococcal Vaccines; Immunotherapy, Active; Staphylococcal Skin Infections; Staphylococcal Infections

Summary: this study is a first-in-human (phase 1) study using three dose levels of an investigational vaccine directed against staphylococcus aureus (sa3ag). this study is primarily designed to assess how safe and well tolerated sa3ag is, but will also describe the immune response over 12 months elicited by sa3ag. additionally, this study will assess the effect of sa3ag vaccine on the number of staphylococcus aureus bacteria that naturally occur on the skin and within the nose and throat.


Eligibility criteria:
inclusion criteria: * healthy adults aged 18 to 24 years or 50 to 85 years who are available for the entire duration of the study, able to be contacted by phone, and able to complete all study procedures, including completion of an electronic diary (e-diary). * men and women who are able to have children, must use a reliable method of birth control for the duration of the study. exclusion criteria: * any major illness that would substantially increase the risk associated with participation in the study, or interfere with the evaluation of the study objectives - this is determined by the local physician. * donation of 250 ml or more of blood within the last 3 months. * condition associated with prolonged bleeding time, including subjects taking anticoagulant medication or antiplatelet therapy. * any contraindication to vaccination or vaccine components. * immunocompromised persons and subjects who receive treatment with immunosuppressive therapy. * previous administration of s. aureus vaccination. * receipt of blood products or immunoglobulins within 12 months prior to study * participation in another trial (not including observational trials) within the last 30 days. * study site personnel or immediate family members (first-degree relatives). * women who are pregnant (as determined by urine pregnancy test) or breast-feeding. * residence in a nursing home or long-term care facility or requirement for semiskilled nursing care. * for subjects aged 65 years or older, a mini-mental state examination (mmse) score of \<=21.

Keywords: staphylococcus aureus vaccine
oasis wound matrix (oasis) mechanism of action

Conditions: Diabetic Foot Ulcers (DFU); Venous Stasis Ulcers (VSU)

Summary: oasis wound matrix (oasis) will be applied to wounds, with sequential biopsy of healing wounds to explore the mechanism of action.

wound types will be diabetic foot ulcers (dfu) and venous stasis ulcers (vsu).

Eligibility criteria:
inclusion criteria: * diabetic foot ulcer (dfu) or venous stasis ulcer (vsu) of the leg, with certain restrictions on size, duration and underlying health exclusion criteria: * contraindications or hypersensitivity to the use of the study medications or their components
a study to evaluate the safety, pharmacokinetics, and activity of ro7566802 as a single agent and in combination with atezolizumab in participants with locally advanced or metastatic solid tumors

Conditions: Locally Advanced Solid Tumors; Recurrent Solid Tumors; Metastatic Solid Tumors

Summary: this is a first-in-human phase i, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of ro7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. participants will be enrolled in 2 stages: dose escalation and expansion.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0-1 * life expectancy \>=3 months, in the investigator's judgment * adequate hematologic and end-organ function * histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care * measurable disease per recist v1.1 * tumor specimen availability, for certain cohorts exclusion criteria: * any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to c1d1, with certain exceptions * active hepatitis b or c * active tuberculosis * positive test for hiv infection * administration of a live, attenuated vaccine (e.g., flumist) within 4 weeks prior to ro7566802 infusion * symptomatic, untreated, or actively progressing central nervous system (cns) metastases * active or history of autoimmune disease * prior allogeneic stem cell or organ transplantation * uncontrolled tumor-related pain * significant cardiovascular disease other protocol-defined inclusion/exclusion criteria may apply.
femoral nerve blockade in endovenous laser

Conditions: Pain

Summary: varicose veins affect a majority of adult population in the western world. they decrease quality of life and may also cause venous ulcers. therefore varicose vein treatments are justified. currently endovenous thermal ablation is a treatment of choice for varicose veins. at the outpatient setting, however, treating both limbs at the same time may be painful to the patient especially, if simultaneous phlebectomies are performed. the study aims to evaluate, if femoral nerve blockade can significantly decrease pain during the procedure without prolonging the stay in the hospital.

varicose veins affect a majority of adult population in the western world. they decrease quality of life and may also cause venous ulcers. therefore varicose vein treatments are justified. thanks to technical advancement open surgery has been replaced by endovenous means. currently endovenous thermal ablation is a golden standard for main trunk disease. for efficient patient and procedure flow majority of thermal ablations are performed at the outpatient setting. however, if patient is suffering from significant varicose veins, treating both legs, may be unpleasant to the patient. aim of the study is, whether addition of femoral nerve blockade to the tumescent anesthesia can decrease pain during the procedure without prolonging the stay in the hospital.

Eligibility criteria:
inclusion criteria: * great saphenous vein insufficiency * ceap class 2-4 exclusion criteria: * neurological diseases * pregnancy * ceap 5-6 * bmi\>40 * allergy to lidocain

Keywords: pain femoral nerve blockade varicose vein
fetal vascular hemodynamic changes in iron deficiency anemia

Conditions: Iron Deficiency Anemia

Summary: iron deficiency anemia is a worldwide medical disorder. so far, it is the most common medical complication in pregnancy specially in developing countries. it is the cause of many adverse effects on mother and fetus and contributes significantly to high maternal mortality. maternal iron deficiency anemia is frequently associated with premature delivery, low birth weight babies


Eligibility criteria:
inclusion criteria: * pregnant women with gestational age 28-32 weeks * singleton pregnancy * iron deficiency anemia. exclusion criteria: * multiple pregnancy * antepartum hemorrhage * major congenital fetal anomalies * any other type of anemia other than iron deficiency anemia * any acute or chronic maternal disease other than iron deficiency anemia.
molecular diagnostic platform for aml

Conditions: Acute Myeloid Leukemia (AML)

Summary: this will be a translational study without any therapeutic intervention, for the purpose of analyzing the diagnostic and molecular results / characterization of adult patients with aml, regardless of the treatment they receive. newly diagnosed or relapsed/resistant aml patients will be included.

this will be a multicenter, translational study without any therapeutic intervention. it will be conducted at 7 central laboratories (hospital universitari i politècnic la fe, hospital universitario de salamanca, hospital 12 de octubre, hospital universitario virgen del rocío, hospital dr. negrín de las palmas de gran canaria, hospital reina sofía de córdoba and clínica universidad de navarra) belonging to the spanish pethema group. the laboratories will receive and process bone marrow and peripheral blood samples of patients with aml at the time of the initial diagnosis or at relapse or resistance (first or subsequent relapse/resistance). the demographic data and clinical characteristics of the patients and of the aml, morphological and molecular response will be collected in case report forms (crfs). since the aim of this study is the molecular diagnosis of aml, all patients with aml will be included, regardless of the treatment (or no treatment at all) they receive. the physicians will receive the report about the molecular diagnosis for flt3, npm1, cbf and pml/rara quickly (\<48-96 hours), in order to provide them with knowledge of the mutational status, that may cause changes to be made during the initial management of the disease. the aim of this project is to set up this rapid screening and diagnostic platform for aml by having specimens sent to 7 centralized reference laboratories across the country, where the molecular characteristics of leukemic cells will be analyzed by qrt-pcr and ngs technologies with high quality standards. this platform will provide homogeneous criteria for assessing the biological characteristics of the different entities that make up the disease. it is expected that samples of marrow and/or blood of 700 patients with aml will be analyzed per year.

Eligibility criteria:
inclusion criteria: * have voluntarily given informed consent for the sending and processing of biological specimens, as well as for the analysis and reporting of the results on the mutation status of their aml. * age greater than or equal to 18 years. * morphological diagnosis of aml or acute leukemia of ambiguous lineage according to who criteria at diagnosis, relapse or resistance. exclusion criteria: * inability of the patient or his/her legal representative to understand and voluntarily sign the informed consent form

Keywords: aml adult molecular
emotional care competency scale for dementia: development and correlations with knowledge, attitudes, and confidence

Conditions: Dementia Patients Care; Emotional

Summary: this study aims to develop an "emotional care competency scale for dementia" targeting long-term care professionals and to explore the relationship between caregivers' emotional care competency and their knowledge, attitudes, and confidence in dementia care. a mixed-methods approach will be employed in two exploratory phases: phase one: scale development participants: purposeful sampling will recruit experienced long-term care professionals. method: conduct qualitative interviews; analyze the collected data using content analysis to code and categorize information; draft the initial version of the emotional care competency scale for dementia based on the results. phase two: scale validation and relationship analysis objective: validate the reliability and validity of the scale and examine the relationship between professionals' emotional care competency and their knowledge, attitudes, and confidence in dementia care. design: longitudinal descriptive correlational study. participants: convenience sampling to recruit participants for two rounds of questionnaire surveys. this study seeks to provide a comprehensive tool for assessing emotional care competencies among dementia care professionals and to understand how these competencies relate to their knowledge, attitudes, and confidence in delivering care.


Eligibility criteria:
inclusion criteria: - aged 18 years or older. currently working in a setting that provides dementia care. currently engaged in nursing or caregiving services in the long-term care sector. able to communicate in mandarin or taiwanese. no history of mental illness. exclusion criteria: - under 18 years of age. suffering from significant physical or psychological illnesses.
effects of daxibotulinumtoxina for blepharospasm and hemifacial spasm

Conditions: Benign Essential Blepharospasm; Hemifacial Spasm

Summary: the goal of this clinical trial is to test the effects of daxibotulinumtoxina-lanm (daxxify) in patients with benign essential blepharospasms (beb) and hemifacial spasms (hfs). the main questions to answer: 1. is there clinically significant difference (measured by jankovic rating scale (jrs) score from base to peak efficacy) for patients with beb and hfs treated with daxxify? 2. what percentage of patients achieve a clinical response? participants historically treated with botox for either beb or hfs will be crossed over to daxxify treatment in order to serve as their own control and examine the efficacy of daxxify.

this will be a single-arm, crossover study, in which each patient is their own historical control using a 2:1 conversion ratio of daxxify to botox units. study participants will be selected through the electronic medical records of ophthalmologists at montefiore medical center. medical documentation on each patient will include information on age, sex, race, benign essential blepharospasm (beb) diagnosis year and duration, hemifacial spasms (hfs) diagnosis year and duration, and past treatments. the immediate effects (desired or undesired) of daxxify observed within 48-72 hours, will be defined as (1) complete relief of spasms (2) partial relief to a tolerable level (3) mild to moderate ocular irritation (4) ptosis. overall efficacy will be evaluated using the base to peak efficacy (recorded in changes to jankovic rating scale (jrs) scores) and be defined as (1) excellent (resolution of signs and symptoms, only requiring injections \> 5-6 months (2) moderate (improvement in signs and symptoms but requiring repeated injections within \< 5 months (3) poor (no improvement in signs and symptoms). adverse side effects will be documented, and daxxify will be discontinued in any patients who develop significant side effects that outweigh the benefits.

Eligibility criteria:
inclusion criteria: * benign essential blepharospasm (beb) or hemifacial spasm (hfs) as diagnosed by an ophthalmologist. * no known neurologic or neuromuscular systematic medications. * no history or surgical intervention for beb or hfs. exclusion criteria: * patients will be excluded if age \< 18, are pregnant, non-willing, or with contra-indications to botulinum toxin.
smoking treatment and anxiety management program

Conditions: Nicotine Dependence

Summary: the smoking treatment and anxiety management program (stamp) is a treatment program focused on helping people manage their anxiety while quitting smoking. the study involves coming in to our clinic for 4 treatment sessions, with follow-ups for up to 2 years (a week 1, week 2, month 1, month 3, month 6, year 1, and year 2 follow-up). participants will be paid $142.50 for their full participation as well as receive 6 weeks of free nicotine replacement patches.


Eligibility criteria:
inclusion criteria: * anxiety sensitivity index greater than 15 * daily smoker for at least 1 year * less than 45 years old * currently smoke at least 8 cigarettes per day * report a motivation to quit smoking exclusion criteria: * history of panic disorder * psychotropic medication use (if not stable for 3 months) * history of significant medical condition * current use of smoking cessation pharmacology * use of other tobacco products * planning to move in the next 6 months

Keywords: cognitive behavioral therapy smoking cessation
nutraceuticals and drug treatment in frail older adults

Conditions: Frailty

Summary: frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. frail older adults present a high risk of adverse events such as disability, hospitalization and mortality. it is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment.

frailty is a multidimensional condition due to reserve loss leading to physical and cognitive impairment that is very common in older adults; in fact, its incidence increases with age. frail older adults present a high-risk of adverse events such as disability, hospitalization and mortality. it is very important to check comorbidities and complications to reduce the incidence of cognitive and physical impairment; hence, clinical evaluation is the main goal to get an early diagnosis and a timely treatment for cognitive impairment. considering this background, the study will investigate the effects of nutraceuticals and drug treatment on cognitive impairment in frail older adults. in this scenario, global cognitive function will be evaluated with mini mental state examination (mmse) and montreal cognitive assessment (moca) test and physical impairment with the fried criteria and 5-metres gait speed test.

Eligibility criteria:
inclusion criteria: * age \> 65 years; * a frailty status. exclusion criteria: * age \< 65 years. * no frailty status. * left ventricular ejection fraction \<25%, with previous myocardial infarction or previous ppci or/and coronary by-pass grafting.

Keywords: frailty cognitive impairment physical impairment older adults
effects of ph3 in diabetic nephropathy

Conditions: Diabetic Nephropathy

Summary: the primary objective of this clinical study is to evaluate the effectiveness and safety of ph3 for patients with diabetic nephropathy. the secondary objectives are to identify the optimal dosage for subsequent studies and to provide basis for the next confirmatory study in study design, endpoints, and study methodologies.


Eligibility criteria:
inclusion criteria: 1. males and females between 18 and 70 years of age with type 1 or type 2 diabetes 2. sitting blood pressure of \<=140/90 mm hg 3. serum creatinine \<=2.0 mg/dl 4. urinary albumin: creatinine ratio between 30 mg/g to 1000 mg/g creatinine (of the first urine sample of the day) 5. hemoglobin a1c \<=8% 6. women of child-bearing potential must test negative in a pregnancy test and take contraception measures to prevent pregnancy and can not be breast-feeding 7. voluntary written consent to participate in this study exclusion criteria: 1. history of major cardiovascular or cerebrovascular events within 6 months prior to screening 2. history of cancer 3. receiving chronic nonsteroidal anti-inflammatory therapy 4. history of diabetic ketoacidosis 5. has clinically significant deviation from normal physical examination findings that, in the principal investigator's judgment, may interfere with the study evaluation or affect subject safety 6. has participated in other investigational trials within 28 days prior to study enrollment 7. has taken herbal medical treatment as prescription medication and/or over-the- counter medication, within 28 days prior to study enrollment. 8. has known allergy to the study drug